Cooley advised Principia Biopharma on its $122.2 million initial public offering of 7,187,500 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares. Lawyers David Peinsipp, Drew Williamson, Barbara Kosacz and Amanda Busch led the Cooley team advising the company.
Bank of America Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as joint book-running managers for the offering. Robert W. Baird acted as lead manager.
Principia Biopharma, which now trades on the Nasdaq Global Select Market as “PRNB,” is a biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.